Welcome. Already a member? Click here to sign in.
New customer? Click here  to begin.
Free Shipping on orders over $39.00
Vet Approved PET Medications - for LESS...   @VetApprovedRx.com
Call Toll Free: 877.847.7389
Show me products used for:   Dogs   Cats    > All <
Search
Search  Go


 
Shop by condition
More options
Pet Filter
Show me products used for:
   Dogs
   Cats
   All



All Products US EPA And FDA Approved

We Ship USPS and FedEx.

Find Us On Facebook
Follow Us On Twitter

 

Shop


Resflor Gold is an antibiotic and anti-inflammatory indicated for treatment of bovine respiratory disease BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pyrexia in beef and non-lactating dairy cattle. Each ml of Resflor Gold contains 300 mg florfenicol and 16.5 mg flunixin as flunixin meglumine. The recommended dosage of Resflor Gold is 6 ml per 100 lbs body weight, given by SQ injection in the neck. Do not administer more than 10 ml per injection site. Florfenicol and flunixin meglumine.

Add this item to your cart:

Item# Size/Desc Qty Price
1000089
100 ml
$0.00
$82.99
  
Item qualifies for FREE SHIPPINGThis item requires a RX
1000090
250 ml
$0.00
$184.99
Item qualifies for FREE SHIPPINGThis item requires a RX
1000091
500 ml
$0.00
$344.99
Item qualifies for FREE SHIPPINGThis item requires a RX

**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.


INDICATIONS:

RESFLOR GOLD® is indicated for treatment of bovine respiratory disease BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pyrexia in beef and non-lactating dairy cattle.

DOSAGE AND ADMINISTRATION:

RESFLOR GOLD® should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight and 2.2 mg flunixin/kg body weight 6 mL/100 lb. Do not administer more than 10 mL at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated. For the 500mL vial, do not puncture the stopper more than 10 times.

RESFLOR GOLD® Dosage Guide*

ANIMAL WEIGHT lbs

DOSAGE mL

100

6.0

200

12.0

300

18.0

400

24.0

500

30.0

600

36.0

700

42.0

800

48.0

900

54.0

1000

60.0

Recommended Injection Location

* Do not administer more than 10 mL at each site.

CONTRAINDICATIONS:

Do not use in animals that have shown hypersensitivity to florfenicol or flunixin.

WARNINGS:

NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains material that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Material Safety Data Sheet MSDS contains more detailed occupational safety information.

For customer service or to obtain a copy of the MSDS, call 1-800-211-3573. For technical assistance or to report suspected adverse reactions, call 1-800-219-9286.

PRECAUTIONS:

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully monitored. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that have not been previously diagnosed. Since many NSAIDs possess the potential to produce gastrointestinal ulceration, concomitant use of RESFLOR GOLD® with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

Flunixin is a cyclo-oxygenase inhibitory NSAID, and as with others in this class, adverse effects may occur with its use. The most frequently reported adverse effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported for other drugs in this class.

Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect.

RESFLOR GOLD®, when administered as directed, may induce a transient reaction at the site of injection and underlying tissues that may result in trim loss of edible tissue at slaughter.

RESIDUE WARNINGS:

Animals intended for human consumption must not be slaughtered within 38 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

 

ADVERSE REACTIONS:

Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle. In cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use of flunixin meglumine.